Autres langues Immunovia AB London S.E.

Actions

0G8X

SE0006091997

Equipement et technologie médicale avancés

Marché Fermé - London S.E. Autres places de cotation 16:45:34 03/11/2025			Varia. 5j.	Varia. 1 janv.
31,92 ^SEK	-32,03%		+16 951,28%	+13 658,62%

15/06	Immunovia présente de nouvelles données avant sa demande de remboursement auprès de Medicare	FW
15/06	Immunovia dévoile de nouvelles données de performance pour PancreaSure avant sa demande de prise en charge par Medicare	CI

Autres langues

15/06	Immunovia announces new performance data for PancreaSure ahead of upcoming application for Medicare coverage
15/06	Immunovia Announces New Performance Data for PancreaSure Ahead of Upcoming Application for Medicare Coverage
10/06	Immunovia publishes final AFFIRM study results in Journal of Clinical Oncology confirming strong diagnostic performance of PancreaSure
10/06	Immunovia Publishes Final Affirm Study Results in Journal of Clinical Oncology Confirming Strong Diagnostic Performance of Pancreasure
13/05	BULLETIN FROM THE ANNUAL GENERAL MEETING ON 13 MAY 2026 IN IMMUNOVIA AB (PUBL)
11/05	Research update Immunovia, Q1 2026: Initial commercialisation phase on track
07/05	Immunovia Q1 operating loss at SEK 18.4 mln
07/05	Immunovia Publishes Interim Report for January-March 2026
07/05	Immunovia AB Reports Earnings Results for the First Quarter Ended March 31, 2026
05/05	Immunovia launches ASSURE registry to evaluate real-world clinical impact of PancreaSure in high-risk pancreatic cancer surveillance
05/05	Immunovia AB Launches Assure Registry To Evaluate Real-World Clinical Impact Of Pancreasure In High-Risk Pancreatic Cancer Surveillance
04/05	Immunovia : Proposal for resolution on (A) option program for board members; and (B) directed issue of warrants and approval of transfer of warrants (Proposal for resolution on A option program for board members and B directed issue of warrants and approval of transfer of warrants 45758458 v6)
04/05	Immunovia invites to a presentation on the Q1 report and 2026 objectives
14/04	Immunovia : Proposal for resolution on (A) option program for management and key persons; and (B) directed issue of warrants and approval of transfer of warrants (Proposal for resolution on A option program for management and key persons and B directed issue of warrants and approval of transfer of warrants)
14/04	Immunovia : Proposal for resolution on (A) option program for board members; and (B) directed issue of warrants and approval of transfer of warrants (Proposal for resolution on A option program for board members and B directed issue of warrants and approval of transfer of warrants )
14/04	Immunovia : Proposal for resolution on authorization of the board to resolve on new issue of shares (Proposal for resolution on authorization regarding issues)
14/04	Immunovia : Annual Report (Immunovia AB publ Annual Report 2025)
14/04	Immunovia : Notice to annual general meeting 2026 (notice of annual general meeting in immunovia ab publ)
14/04	Immunovia : Statement from nomination committee (Statement from nomination committee 2026)
13/04	NOTICE OF ANNUAL GENERAL MEETING IN IMMUNOVIA AB (PUBL)
10/04	Immunovia publishes the Annual Report for 2025
10/04	Immunovia AB Auditor Raises 'Going Concern' Doubt
10/04	Immunovia : Remuneration Report (Remuneration Report 2026 Updated)
25/02	Research update Immunovia Q4 2025: Targeting Medicare sub-mission by mid-2026
24/02	Immunovia AB Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025